TOKYO -- Takeda Pharmaceutical plans seek approval from U.S. regulators to sell a dengue fever vaccine there, aiming to become the first Japanese company to enter the American vaccine market, Nikkei has learned.
Takeda's plan to file an application with the U.S. Food and Drug Administration was revealed by Takeda CEO Christophe Weber. Details, such as the timing of the filing and production plans, will be ironed out later.
